Circulating microRNA as new prognostic markers in de novo chronic Myeloid Leukemia

Abstract

Chronic Myeloid Leukemia (CML) is a malignant clonal hematopoietic stem cell disease. The discovery of the Philadelphia chromosome and subsequent identification of the gene bcr-abl have led to understanding the biology of the disease and the development of target-specific drugs, as well as molecular methods for monitoring the disease. The current focus of research in the CML is facing the greatest understanding of the molecular and epigenetic mechanisms that lead to therapy resistance and disease progression. Recent studies show that the expression of specific microRNAs modulates oncogenes and tumor suppressor genes involved in cancer development. Against this trend will evaluate the profile of miRNAs from 16 patients with CML, newly diagnosed (CML de novo. PCR system will use miRNA arrays that can detect the expression level of approximately 700 miRNAs functional human simultaneously by real-time quantitative PCR (96-Assay Human miScript Qiagen ®). Our expectation with this study is to identify a specific microRNA signature and compare the results found in regular project FAPESP 2011/50629-7, which studies the profile of micro-RNAs of patients with minimal residual leukemia.(AU)